

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Meisner Derek M</u>  (Last) (First) (Middle) C/O ACUMEN PHARMACEUTICALS, INC. 1210-1220 WASHINGTON STREET, SUITE 210  (Street) NEWTON MA 02465  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Acumen Pharmaceuticals, Inc. [ ABOS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Legal Officer &amp; Corp Sec</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/03/2025</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2025		S		11,122 <sup>(1)</sup>	D	\$1.8437 <sup>(2)</sup>	97,745	D	
Common Stock	01/06/2025		A		66,800 <sup>(3)</sup>	A	\$0	164,545	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (right to buy)	\$1.85	01/06/2025		A		100,300		(4)	01/06/2035	Common Stock	100,300	\$0	100,300	D	

**Explanation of Responses:**

- Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$1.7750 to \$1.9300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

**Remarks:**

/s/ Derek Meisner 01/07/2025  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.